Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2015 | Ardelyx | Post-IPO Equity | 77.8M |
12/2013 | Stem Cell Therapeutics | Post-IPO Equity | 0 |
12/2014 | Naurex | Series C | 0 |
10/2013 | Arno Therapeutics | Post-IPO Equity | 0 |
9/2022 | RooLife Group | Post-IPO Debt | 1M |
1/2015 | Global Blood Therapeutics | Series B | 48M |
8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
8/2014 | Dermira | Series C | 51M |
4/2014 | Adverum Biotechnologies | Series B | 55M |
11/2014 | Blueprint Medicines | Series C | 50M |
2/2015 | Cidara Therapeutics | Series B | 42M |
4/2017 | Epic Sciences | Series D | 0 |
3/2015 | Champions Oncology | Post-IPO Equity | 14M |
4/2017 | Epic Sciences | Series D | 0 |
6/2015 | Ardelyx | Post-IPO Equity | 0 |
3/2015 | Champions Oncology | Post-IPO Equity | 0 |
2/2015 | Cidara Therapeutics | Series B | 0 |
1/2015 | Global Blood Therapeutics | Series B | 0 |
12/2014 | Naurex | Series C | 0 |
11/2014 | Blueprint Medicines | Series C | 0 |
8/2014 | Bellicum Pharmaceuticals | Series C | 0 |
8/2014 | Dermira | Series C | 0 |
4/2014 | Adverum Biotechnologies | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|